Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors
Humans have two glutaminase genes, GLS (GLS1) and GLS2, each of which has two alternative transcripts: the kidney isoform (KGA) and glutaminase C (GAC) for GLS, and the liver isoform (LGA) and glutaminase B (GAB) for GLS2. Initial hit compound (Z)-5-((1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)m...
Saved in:
Published in | Journal of medicinal chemistry Vol. 60; no. 13; pp. 5599 - 5612 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
WASHINGTON
American Chemical Society
13.07.2017
Amer Chemical Soc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Humans have two glutaminase genes, GLS (GLS1) and GLS2, each of which has two alternative transcripts: the kidney isoform (KGA) and glutaminase C (GAC) for GLS, and the liver isoform (LGA) and glutaminase B (GAB) for GLS2. Initial hit compound (Z)-5-((1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methylene)thiazolidine-2,4-dione (2), a thiazolidine-2,4-dione, was obtained from a high throughput screening of 40 000 compounds against KGA. Subsequently, a series of thiazolidine-2,4-dione derivatives was synthesized. Most of these were found to inhibit KGA and GAC with comparable activities, were less potent inhibitors of GAB, and were moderately selective for GLS1 over GLS2. The relationships between chemical structure, activity, and selectivity were investigated. The lead compounds obtained were found to (1) offer in vitro cellular activities for inhibiting cell growth, clonogenicity, and cellular glutamate production, (2) exhibit high concentrations of exposure in plasma by a pharmacokinetic study, and (3) reduce the tumor size of xenografted human pancreatic AsPC-1 carcinoma cells in mice. |
---|---|
AbstractList | Humans have two glutaminase genes, GLS (GLS1) and GLS2, each of which has two alternative transcripts: the kidney isoform (KGA) and glutaminase C (GAC) for GLS, and the liver isoform (LGA) and glutaminase B (GAB) for GLS2. Initial hit compound (Z)-5((1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methylene)thiazolidine-2,4-dione (2), a thiazolidine-2,4-dione, was obtained from a high throughput screening of 40 000 compounds against KGA. Subsequently, a series of thiazolidine-2,4-dione derivatives was synthesized. Most of these were found to inhibit KGA and GAC with comparable activities, were less potent inhibitors of GAB, and were moderately selective for GLS1 over GLS2. The relationships between chemical structure, activity, and selectivity were investigated. The lead compounds obtained were found to (1) offer in vitro cellular activities for inhibiting cell growth, clonogenicity, and cellular glutamate production, (2) exhibit high concentrations of exposure in plasma by a pharmacokinetic study, and (3) reduce the tumor size of xenografted human pancreatic AsPC-1 carcinoma cells in mice. Humans have two glutaminase genes, GLS (GLS1) and GLS2, each of which has two alternative transcripts: the kidney isoform (KGA) and glutaminase C (GAC) for GLS, and the liver isoform (LGA) and glutaminase B (GAB) for GLS2. Initial hit compound (Z)-5-((1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methylene)thiazolidine-2,4-dione (2), a thiazolidine-2,4-dione, was obtained from a high throughput screening of 40 000 compounds against KGA. Subsequently, a series of thiazolidine-2,4-dione derivatives was synthesized. Most of these were found to inhibit KGA and GAC with comparable activities, were less potent inhibitors of GAB, and were moderately selective for GLS1 over GLS2. The relationships between chemical structure, activity, and selectivity were investigated. The lead compounds obtained were found to (1) offer in vitro cellular activities for inhibiting cell growth, clonogenicity, and cellular glutamate production, (2) exhibit high concentrations of exposure in plasma by a pharmacokinetic study, and (3) reduce the tumor size of xenografted human pancreatic AsPC-1 carcinoma cells in mice. |
Author | Yeh, Teng-Kuang Shih, Chuan Lee, Yue-Zhi Chu, Kuang-Feng Kuo, Ching-Chuan Ke, Yi-Yu Wu, Szu-Huei Tsou, Lun Kelvin Yang, Cheng-Wei Lee, Shiow-Ju Lin, Li-Mei Hsu, Hsing-Yu Kuo, Po-Chu Sun, Manwu Chang, Hsin-Yu Chen, Chiung-Tong Liu, Yu-Wei Song, Jen-Shin |
Author_xml | – sequence: 1 givenname: Teng-Kuang surname: Yeh fullname: Yeh, Teng-Kuang – sequence: 2 givenname: Ching-Chuan surname: Kuo fullname: Kuo, Ching-Chuan – sequence: 3 givenname: Yue-Zhi orcidid: 0000-0001-8640-9525 surname: Lee fullname: Lee, Yue-Zhi – sequence: 4 givenname: Yi-Yu surname: Ke fullname: Ke, Yi-Yu – sequence: 5 givenname: Kuang-Feng surname: Chu fullname: Chu, Kuang-Feng – sequence: 6 givenname: Hsing-Yu surname: Hsu fullname: Hsu, Hsing-Yu – sequence: 7 givenname: Hsin-Yu surname: Chang fullname: Chang, Hsin-Yu – sequence: 8 givenname: Yu-Wei orcidid: 0000-0001-8495-4941 surname: Liu fullname: Liu, Yu-Wei – sequence: 9 givenname: Jen-Shin surname: Song fullname: Song, Jen-Shin – sequence: 10 givenname: Cheng-Wei orcidid: 0000-0002-3994-475X surname: Yang fullname: Yang, Cheng-Wei – sequence: 11 givenname: Li-Mei surname: Lin fullname: Lin, Li-Mei – sequence: 12 givenname: Manwu surname: Sun fullname: Sun, Manwu – sequence: 13 givenname: Szu-Huei surname: Wu fullname: Wu, Szu-Huei – sequence: 14 givenname: Po-Chu surname: Kuo fullname: Kuo, Po-Chu – sequence: 15 givenname: Chuan surname: Shih fullname: Shih, Chuan – sequence: 16 givenname: Chiung-Tong surname: Chen fullname: Chen, Chiung-Tong – sequence: 17 givenname: Lun Kelvin orcidid: 0000-0002-1593-5226 surname: Tsou fullname: Tsou, Lun Kelvin email: kelvintsou@nhri.org.tw – sequence: 18 givenname: Shiow-Ju orcidid: 0000-0003-4012-0149 surname: Lee fullname: Lee, Shiow-Ju email: slee@nhri.org.tw |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28609101$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUFv1DAQhS1URLeFf4CQj0hslrHjJM4RpaVUquBAOUcTZ8K6SuxiJ4vKr8fb3faIkCyN5fneePTeGTtx3hFjbwVsBEjxEU3c3E3Umy1Nm6oDkFq-YCtRSMiUBnXCVulNZrKU-Sk7i_EOAHIh81fsVOoSagFixcIFRfvTrfn3Bzdv0z2uObqeX-5wXHC23nE_8NutxT9-tL11lMm1yvrUIH5Bwe4StKPIMR3-1e9o5M2IMe5lV-My42QdRuLXbms7O_sQX7OXA46R3hzrOfvx-fK2-ZLdfLu6bj7dZJgrPWcyr4UwvalTKbHUCEWHBUrdoSh6oQbQRmhV9HVJoipEKQtR5Qo7IKGpwvycvT_MvQ_-10JxbicbDY0jOvJLbEUNdaXKSlUJVQfUBB9joKG9D3bC8NAKaPdut8nt9snt9uh2kr07_rB0qfcserI3AR8OwG_q_BCNJWfoGUt5KCiqUtWwTyrR-v_pxs6P8TR-cXOSwkH6uKdfgkvO_nv5v_l9sHQ |
CitedBy_id | crossref_primary_10_1016_j_bbcan_2018_07_007 crossref_primary_10_1016_j_ejmech_2020_112980 crossref_primary_10_1021_acsptsci_8b00047 crossref_primary_10_1007_s41061_020_0298_4 crossref_primary_10_14233_ajchem_2020_22565 crossref_primary_10_3390_ijms232315296 crossref_primary_10_1021_acsmedchemlett_3c00375 crossref_primary_10_3390_cancers15235566 crossref_primary_10_1016_j_ejmech_2023_115306 crossref_primary_10_4155_fdd_2022_0011 crossref_primary_10_1021_acs_joc_2c00748 crossref_primary_10_3389_fonc_2020_589508 crossref_primary_10_1016_j_bmcl_2019_07_014 crossref_primary_10_1021_acs_jmedchem_0c00523 crossref_primary_10_1021_acs_jmedchem_8b00327 crossref_primary_10_1097_CM9_0000000000002758 crossref_primary_10_1021_acs_jmedchem_8b00961 crossref_primary_10_2174_0929867326666190416165004 crossref_primary_10_1016_j_cbi_2021_109433 crossref_primary_10_1016_j_ejmech_2018_11_066 crossref_primary_10_1021_acs_jmedchem_8b01198 crossref_primary_10_1021_acs_jmedchem_9b01035 crossref_primary_10_3390_ijms24010012 crossref_primary_10_1038_s41598_021_88816_1 crossref_primary_10_1021_acsptsci_1c00226 crossref_primary_10_1002_ajoc_201800274 crossref_primary_10_1016_j_canlet_2019_09_011 |
Cites_doi | 10.1016/j.drudis.2013.10.008 10.1073/pnas.1002459107 10.1038/srep03827 10.1021/jm901137j 10.1002/jcc.21287 10.1042/BJ20070039 10.1158/0008-5472.CAN-09-1947 10.1016/j.cmet.2011.12.009 10.1016/j.bmcl.2017.01.057 10.1111/j.2042-7158.2012.01567.x 10.4155/fmc-2016-0190 10.1016/j.ejmech.2016.09.003 10.1042/BJ20040996 10.7554/eLife.10727 10.1073/pnas.1414056112 10.1155/2014/312640 10.4161/cc.24478 10.1016/S1046-5928(03)00161-X 10.1073/pnas.1001006107 10.1021/bi201613d 10.1016/j.ccr.2010.08.009 10.1158/1535-7163.MCT-13-0870 10.1210/me.2013-1427 10.1021/jm301191p 10.18632/oncotarget.208 10.2174/1566524011313040005 10.18632/oncotarget.5821 10.1042/bj20021360 10.1200/jco.2008.26.15_suppl.2533 10.18632/oncotarget.190 10.1016/S0959-8049(99)00099-4 10.18632/oncotarget.2173 10.18632/oncotarget.1862 |
ContentType | Journal Article |
Copyright | Copyright © 2017 American Chemical
Society |
Copyright_xml | – notice: Copyright © 2017 American Chemical Society |
DBID | 1KM BLEPL DTL GYRTJ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1021/acs.jmedchem.7b00282 |
DatabaseName | Index Chemicus Web of Science Core Collection Science Citation Index Expanded Web of Science - Science Citation Index Expanded - 2017 Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | Web of Science MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | Web of Science MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 1KM name: Index Chemicus url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC sourceTypes: Enrichment Source Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-4804 |
EndPage | 5612 |
ExternalDocumentID | 10_1021_acs_jmedchem_7b00282 28609101 000405764900022 c657968397 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Ministry of Economic Affairs, Taiwan R.O.C.; Ministry of Economic Affairs, Taiwan grantid: 101-EC-17-A-02-04-1099; 102-EC-17-A-02-04-1099; 103-EC-17-A-22-1099; 104-EC-17-A-22-1099; 105-EC-17-A-22-1099 |
GroupedDBID | - .K2 55A 5GY 5RE 5VS 7~N AABXI ABFLS ABMVS ABOCM ABPTK ABUCX ACGFS ACJ ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 DU5 EBS ED ED~ EJD F5P GNL IH9 IHE JG JG~ K2 L7B LG6 P2P ROL TN5 UI2 VF5 VG9 W1F WH7 X XFK YZZ ZY4 --- -~X 1KM 4.4 6P2 AAHBH ABJNI ABQRX ABTAH ACGFO ADHLV AGXLV AHGAQ BLEPL CUPRZ DTL GGK GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED IH2 XSW YQT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-a348t-23911cdc99116a68a05ba5a28ba15d14f08c1845d96e17516251734ab0e18e7a3 |
IEDL.DBID | ACS |
ISICitedReferencesCount | 28 |
ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000405764900022 |
ISSN | 0022-2623 |
IngestDate | Fri Aug 16 09:26:20 EDT 2024 Fri Aug 23 00:27:50 EDT 2024 Sat Sep 28 08:40:23 EDT 2024 Wed Sep 18 05:47:44 EDT 2024 Fri Nov 01 20:09:48 EDT 2024 Thu Aug 27 13:42:30 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | CELLS KIDNEY-TYPE GLUTAMINASE METABOLISM MECHANISM ALLOSTERIC INHIBITOR MITOCHONDRIAL GLUTAMINASE CANCER EXPRESSION CARCINOMA AGONISTS |
Language | English |
LinkModel | DirectLink |
LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
MergedId | FETCHMERGED-LOGICAL-a348t-23911cdc99116a68a05ba5a28ba15d14f08c1845d96e17516251734ab0e18e7a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-3994-475X 0000-0001-8640-9525 0000-0001-8495-4941 0000-0003-4012-0149 0000-0002-1593-5226 |
PMID | 28609101 |
PQID | 1909746747 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_1909746747 acs_journals_10_1021_acs_jmedchem_7b00282 pubmed_primary_28609101 crossref_primary_10_1021_acs_jmedchem_7b00282 webofscience_primary_000405764900022 webofscience_primary_000405764900022CitationCount |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N ACJ VG9 W1F ACS AEESW AFEFF .K2 ABMVS ABUCX IH9 BAANH AQSVZ ED~ UI2 |
PublicationCentury | 2000 |
PublicationDate | 20170713 2017-07-13 |
PublicationDateYYYYMMDD | 2017-07-13 |
PublicationDate_xml | – month: 07 year: 2017 text: 20170713 day: 13 |
PublicationDecade | 2010 |
PublicationPlace | WASHINGTON |
PublicationPlace_xml | – name: WASHINGTON – name: United States |
PublicationTitle | Journal of medicinal chemistry |
PublicationTitleAbbrev | J MED CHEM |
PublicationTitleAlternate | J. Med. Chem |
PublicationYear | 2017 |
Publisher | American Chemical Society Amer Chemical Soc |
Publisher_xml | – name: American Chemical Society – name: Amer Chemical Soc |
References | Le, A (WOS:000299656700015) 2012; 15 Gross, MI (WOS:000334342300012) 2014; 13 Hu, WW (WOS:000276892300063) 2010; 107 Giacobbe, A (WOS:000322758600014) 2013; 12 Cheng, L (WOS:000395967900025) 2017; 27 Mueller, C (WOS:000208457400570) 2008; 26 Baell, JB (WOS:000276096300004) 2010; 53 Chou, TC (WOS:000278485500003) 2010; 70 Chen, SR (WOS:000396804600020) 2017; 126 DeLaBarre, B (WOS:000298118700002) 2011; 50 Mates, JM (WOS:000317117400005) 2013; 13 Thangavelu, K (WOS:000330045000004) 2014; 4 Robinson, MM (WOS:000249537700005) 2007; 406 Huang, F (WOS:000335227200027) 2014; 7 Kenny, J (WOS:000185553900017) 2003; 31 Shukla, K (WOS:000312227300021) 2012; 55 Wu, F (WOS:000081739300027) 1999; 35 Zhang, C (WOS:000369062000001) 2016; 5 Stalnecker, CA (WOS:000347732300042) 2015; 112 Katt, WP (WOS:000393683500007) 2017; 9 Wolf, A (WOS:000293506100009) 2010; 1 Liu, J (WOS:000336966600025) 2014; 5 ALLEN, L (WOS:A1980JC23900015) 1980; 27 Tacar, O (WOS:000314212400001) 2013; 65 Brooks, BR (WOS:000267269600001) 2009; 30 Hidalgo, M (WOS:000076877400023) 1998; 4 Wang, JB (WOS:000281881500004) 2010; 18 Xiao, DB (WOS:000366115500021) 2015; 6 Katt, WP (WOS:000336196500013) 2014; 19 Erickson, JW (WOS:000293506500006) 2010; 1 Perez-Gomez, C (WOS:000228099500015) 2005; 386 Turner, A (WOS:000181471700005) 2003; 370 Chang, H (WOS:000338048800001) 2014 Suzuki, S (WOS:000276892300064) 2010; 107 Wright, MB (WOS:000346837100002) 2014; 28 ref9/cit9 ref6/cit6 ref3/cit3 ref27/cit27 ref18/cit18 ref11/cit11 ref25/cit25 ref16/cit16 ref29/cit29 Hidalgo M. (ref23/cit23) 1998; 4 ref32/cit32 ref14/cit14 ref8/cit8 ref5/cit5 ref31/cit31 ref2/cit2 ref34/cit34 ref28/cit28 ref20/cit20 Allen L. (ref22/cit22) 1980; 27 ref10/cit10 ref26/cit26 ref35/cit35 ref19/cit19 ref21/cit21 ref12/cit12 ref15/cit15 Huang F. (ref17/cit17) 2014; 7 ref13/cit13 ref33/cit33 ref4/cit4 ref30/cit30 ref1/cit1 ref24/cit24 ref7/cit7 |
References_xml | – volume: 13 start-page: 514 year: 2013 ident: WOS:000317117400005 article-title: Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer publication-title: CURRENT MOLECULAR MEDICINE contributor: fullname: Mates, JM – volume: 19 start-page: 450 year: 2014 ident: WOS:000336196500013 article-title: Glutaminase regulation in cancer cells: a druggable chain of events publication-title: DRUG DISCOVERY TODAY doi: 10.1016/j.drudis.2013.10.008 contributor: fullname: Katt, WP – volume: 370 start-page: 403 year: 2003 ident: WOS:000181471700005 article-title: Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas publication-title: BIOCHEMICAL JOURNAL contributor: fullname: Turner, A – volume: 26 year: 2008 ident: WOS:000208457400570 article-title: A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors publication-title: JOURNAL OF CLINICAL ONCOLOGY contributor: fullname: Mueller, C – volume: 107 start-page: 7461 year: 2010 ident: WOS:000276892300064 article-title: Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species publication-title: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA doi: 10.1073/pnas.1002459107 contributor: fullname: Suzuki, S – volume: 4 start-page: ARTN 3827 year: 2014 ident: WOS:000330045000004 article-title: Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA) publication-title: SCIENTIFIC REPORTS doi: 10.1038/srep03827 contributor: fullname: Thangavelu, K – volume: 53 start-page: 2719 year: 2010 ident: WOS:000276096300004 article-title: New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm901137j contributor: fullname: Baell, JB – volume: 30 start-page: 1545 year: 2009 ident: WOS:000267269600001 article-title: CHARMM: The Biomolecular Simulation Program publication-title: JOURNAL OF COMPUTATIONAL CHEMISTRY doi: 10.1002/jcc.21287 contributor: fullname: Brooks, BR – volume: 7 start-page: 1093 year: 2014 ident: WOS:000335227200027 article-title: Expression of glutaminase is upregulated in colorectal cancer and of clinical significance publication-title: INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY contributor: fullname: Huang, F – volume: 406 start-page: 407 year: 2007 ident: WOS:000249537700005 article-title: Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) publication-title: BIOCHEMICAL JOURNAL doi: 10.1042/BJ20070039 contributor: fullname: Robinson, MM – volume: 70 start-page: 440 year: 2010 ident: WOS:000278485500003 article-title: Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method publication-title: CANCER RESEARCH doi: 10.1158/0008-5472.CAN-09-1947 contributor: fullname: Chou, TC – volume: 15 start-page: 110 year: 2012 ident: WOS:000299656700015 article-title: Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells publication-title: CELL METABOLISM doi: 10.1016/j.cmet.2011.12.009 contributor: fullname: Le, A – volume: 6 start-page: 40655 year: 2015 ident: WOS:000366115500021 article-title: Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2 publication-title: ONCOTARGET contributor: fullname: Xiao, DB – volume: 27 start-page: 1243 year: 2017 ident: WOS:000395967900025 article-title: Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor publication-title: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS doi: 10.1016/j.bmcl.2017.01.057 contributor: fullname: Cheng, L – volume: 65 start-page: 157 year: 2013 ident: WOS:000314212400001 article-title: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems publication-title: JOURNAL OF PHARMACY AND PHARMACOLOGY doi: 10.1111/j.2042-7158.2012.01567.x contributor: fullname: Tacar, O – volume: 27 start-page: 175 year: 1980 ident: WOS:A1980JC23900015 article-title: INHIBITION OF GAMMA-GLUTAMYL-TRANSFERASE TRANSPEPTIDASE FROM HUMAN PANCREATIC-CARCINOMA CELLS BY (ALPHA-S,5S)-ALPHA-AMINO-3-CHLORO-4,5-DIHYDRO-5-ISOXAZOLEACETIC ACID (AT-125 - NSC-163501) publication-title: RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY contributor: fullname: ALLEN, L – volume: 9 start-page: 223 year: 2017 ident: WOS:000393683500007 article-title: A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis publication-title: FUTURE MEDICINAL CHEMISTRY doi: 10.4155/fmc-2016-0190 contributor: fullname: Katt, WP – volume: 126 start-page: 202 year: 2017 ident: WOS:000396804600020 article-title: Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1016/j.ejmech.2016.09.003 contributor: fullname: Chen, SR – volume: 386 start-page: 535 year: 2005 ident: WOS:000228099500015 article-title: Co-expression of glutaminase K and L isoenzymes in human tumour cells publication-title: BIOCHEMICAL JOURNAL doi: 10.1042/BJ20040996 contributor: fullname: Perez-Gomez, C – volume: 5 start-page: ARTN e10727 year: 2016 ident: WOS:000369062000001 article-title: Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis publication-title: ELIFE doi: 10.7554/eLife.10727 contributor: fullname: Zhang, C – volume: 4 start-page: 2763 year: 1998 ident: WOS:000076877400023 article-title: A phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies publication-title: CLINICAL CANCER RESEARCH contributor: fullname: Hidalgo, M – volume: 112 start-page: 394 year: 2015 ident: WOS:000347732300042 article-title: Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells publication-title: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA doi: 10.1073/pnas.1414056112 contributor: fullname: Stalnecker, CA – start-page: ARTN 312640 year: 2014 ident: WOS:000338048800001 article-title: Portfolio Selection with Liability and Affine Interest Rate in the HARA Utility Framework publication-title: ABSTRACT AND APPLIED ANALYSIS doi: 10.1155/2014/312640 contributor: fullname: Chang, H – volume: 1 start-page: 734 year: 2010 ident: WOS:000293506500006 article-title: Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism? publication-title: ONCOTARGET contributor: fullname: Erickson, JW – volume: 5 start-page: 2635 year: 2014 ident: WOS:000336966600025 article-title: Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma publication-title: ONCOTARGET contributor: fullname: Liu, J – volume: 35 start-page: 1155 year: 1999 ident: WOS:000081739300027 article-title: A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): Disruption of mitochondria publication-title: EUROPEAN JOURNAL OF CANCER contributor: fullname: Wu, F – volume: 12 start-page: 1395 year: 2013 ident: WOS:000322758600014 article-title: p63 regulates glutaminase 2 expression publication-title: CELL CYCLE doi: 10.4161/cc.24478 contributor: fullname: Giacobbe, A – volume: 31 start-page: 140 year: 2003 ident: WOS:000185553900017 article-title: Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase publication-title: PROTEIN EXPRESSION AND PURIFICATION doi: 10.1016/S1046-5928(03)00161-X contributor: fullname: Kenny, J – volume: 107 start-page: 7455 year: 2010 ident: WOS:000276892300063 article-title: Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function publication-title: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA doi: 10.1073/pnas.1001006107 contributor: fullname: Hu, WW – volume: 50 start-page: 10764 year: 2011 ident: WOS:000298118700002 article-title: Full-Length Human Glutaminase in Complex with an Allosteric Inhibitor publication-title: BIOCHEMISTRY doi: 10.1021/bi201613d contributor: fullname: DeLaBarre, B – volume: 18 start-page: 207 year: 2010 ident: WOS:000281881500004 article-title: Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation publication-title: CANCER CELL doi: 10.1016/j.ccr.2010.08.009 contributor: fullname: Wang, JB – volume: 13 start-page: 890 year: 2014 ident: WOS:000334342300012 article-title: Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer publication-title: MOLECULAR CANCER THERAPEUTICS doi: 10.1158/1535-7163.MCT-13-0870 contributor: fullname: Gross, MI – volume: 1 start-page: 552 year: 2010 ident: WOS:000293506100009 article-title: Targeting Metabolic Remodeling in Glioblastoma Multiforme publication-title: ONCOTARGET contributor: fullname: Wolf, A – volume: 28 start-page: 1756 year: 2014 ident: WOS:000346837100002 article-title: Minireview: Challenges and Opportunities in Development of PPAR Agonists publication-title: MOLECULAR ENDOCRINOLOGY doi: 10.1210/me.2013-1427 contributor: fullname: Wright, MB – volume: 55 start-page: 10551 year: 2012 ident: WOS:000312227300021 article-title: Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm301191p contributor: fullname: Shukla, K – ident: ref2/cit2 doi: 10.18632/oncotarget.208 – ident: ref13/cit13 doi: 10.1073/pnas.1001006107 – ident: ref29/cit29 doi: 10.1210/me.2013-1427 – ident: ref32/cit32 doi: 10.1016/S1046-5928(03)00161-X – volume: 7 start-page: 1093 issue: 3 year: 2014 ident: ref17/cit17 publication-title: Int. J. Clin. Exp. Pathol. contributor: fullname: Huang F. – ident: ref8/cit8 doi: 10.1158/1535-7163.MCT-13-0870 – ident: ref3/cit3 doi: 10.2174/1566524011313040005 – ident: ref10/cit10 doi: 10.18632/oncotarget.5821 – ident: ref34/cit34 doi: 10.1002/jcc.21287 – ident: ref15/cit15 doi: 10.1042/bj20021360 – ident: ref21/cit21 doi: 10.1200/jco.2008.26.15_suppl.2533 – ident: ref30/cit30 doi: 10.1021/jm901137j – ident: ref33/cit33 doi: 10.1042/BJ20070039 – ident: ref1/cit1 doi: 10.18632/oncotarget.190 – ident: ref35/cit35 doi: 10.1158/0008-5472.CAN-09-1947 – ident: ref4/cit4 doi: 10.1016/j.cmet.2011.12.009 – ident: ref11/cit11 doi: 10.7554/eLife.10727 – volume: 4 start-page: 2763 issue: 11 year: 1998 ident: ref23/cit23 publication-title: Clin. Cancer Res. contributor: fullname: Hidalgo M. – ident: ref6/cit6 doi: 10.1016/j.ccr.2010.08.009 – ident: ref24/cit24 doi: 10.1016/j.bmcl.2017.01.057 – ident: ref31/cit31 doi: 10.1016/j.ejmech.2016.09.003 – ident: ref20/cit20 doi: 10.1016/S0959-8049(99)00099-4 – ident: ref26/cit26 doi: 10.4155/fmc-2016-0190 – ident: ref7/cit7 doi: 10.1021/jm301191p – volume: 27 start-page: 175 issue: 1 year: 1980 ident: ref22/cit22 publication-title: Res. Commun. Chem. Pathol. Pharmacol. contributor: fullname: Allen L. – ident: ref27/cit27 doi: 10.1073/pnas.1414056112 – ident: ref9/cit9 doi: 10.18632/oncotarget.2173 – ident: ref14/cit14 doi: 10.1073/pnas.1002459107 – ident: ref16/cit16 doi: 10.1042/BJ20040996 – ident: ref19/cit19 doi: 10.1038/srep03827 – ident: ref28/cit28 doi: 10.1111/j.2042-7158.2012.01567.x – ident: ref25/cit25 doi: 10.1021/bi201613d – ident: ref18/cit18 doi: 10.18632/oncotarget.1862 – ident: ref5/cit5 doi: 10.1016/j.drudis.2013.10.008 – ident: ref12/cit12 doi: 10.4161/cc.24478 |
SSID | ssj0003123 |
Score | 2.4173298 |
Snippet | Humans have two glutaminase genes, GLS (GLS1) and GLS2, each of which has two alternative transcripts: the kidney isoform (KGA) and glutaminase C (GAC) for... |
Source | Web of Science |
SourceID | proquest crossref pubmed webofscience acs |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5599 |
SubjectTerms | Animals Antineoplastic Agents - blood Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Line, Tumor Cell Proliferation - drug effects Chemistry, Medicinal Drug Design Enzyme Inhibitors - blood Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Glutaminase - antagonists & inhibitors Glutaminase - metabolism Humans Life Sciences & Biomedicine Male Mice Mice, Inbred BALB C Mice, Nude Models, Molecular Pancreas - drug effects Pancreas - metabolism Pancreas - pathology Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pharmacology & Pharmacy Rats Rats, Sprague-Dawley Science & Technology Thiazolidinediones - blood Thiazolidinediones - chemistry Thiazolidinediones - pharmacology Thiazolidinediones - therapeutic use |
Title | Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors |
URI | http://dx.doi.org/10.1021/acs.jmedchem.7b00282 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000405764900022 https://www.ncbi.nlm.nih.gov/pubmed/28609101 https://search.proquest.com/docview/1909746747 |
Volume | 60 |
WOS | 000405764900022 |
WOSCitedRecordID | wos000405764900022 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BOcCFR3k0FJCRqkpImyW2Eyc-VtuWwqFUaiv1FtmOo6aPLGqylba_vmMn2QUKokg5ORPHjxnPZ3n8DcBGSQsXH46GpKUJY8PTUCcyCmUWWaN4Wirjoy32xd5x_O0kOVluFH8_wWf0szLN-MwFK57ay3HabRIewiOWRtKlatiaHC5WXk4ZH9jBGfr14arcX2pxDsk0vzqkOyjzjw7JO5_dZ_B9uMLTxZycj2etHpubu4yO9-zXc3ja41Cy1SnOC3hg61V4PBnSv63C5kFHaj0fkaPlHa1mRDbJwZLuev4SrrZ9EMiIHM5rRJNNhTKqLsjOgkecTEuso1I304sKXaUN2SgOC0eRRLbRAK4993hDFD5kf3ptL4hP1ek--4KGoVy0TmPJ1_q00pXLDvQKjnd3jiZ7YZ_JIVQ8ztqQcVxTTWEQjFKhRKaiRKtEsUwrmhQ0LqPM4FYzKaSwiGeocERqPFY6sjSzqeKvYaXGVq0BkUpTK1IdWwSb2mhZulUIC7nmIjVlAJ9wZPPeEpvcH7IzmvvCfrjzfrgDCIepz3905B7_kP846EeOs-GOVlRtpzP8i4ykT9ySBvCmU5xFjSwTDpTRADZ-1qTFewerETWLWHo2ogDofcQmPYW7oy5o3_5Hp9fhCXPQxJGD8new0l7N7HsEVq3-4K3pFv6RHVU |
link.rule.ids | 315,783,787,2774,27090,27938,27939,57072,57122 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZT9wwEB5R-kBfetArtKWuhJAqrZc4zvmIFujS0hUSS8VbZDuOSEuziGSRll_fsXMsvdQi5clxJj5mPJ_l8TcAWznLTHw4GpJMFPUVj6gMEpcmsauV4FEulI22mITjU__jWXC2AkF3FwYbUaGkyh7iL9kF2I4p-2piFs_192HU7BXuwf0gciOTuGB3dNIvwJx5vCMJ99C9dzfm_iLF-CVV_eyXfgObf_RL1gcdPIIvfett6Mm34byWQ3XzC7Hjnbv3GB62qJTsNmr0BFZ0uQ5roy4Z3DpsHzcU14sBmS5vbFUDsk2Ol-TXi6dwtWdDQgbkZFEitqwKrCPKjOz3rOJklqOMQtzMLgp0nJp6A59mhjCJ7KE5XFsm8ooIfMhkdq0viE3caT77gGYiTOxOpclheV7IwuQKeganB_vT0Zi2eR2o4H5cU4_jCqsyhdCUhSKMhRtIEQgvloIFGfNzN1a48QyyJNSIblhoaNW4L6SrWawjwZ_DaomtegkkEZLpMJK-RugplUxysyZhIZc8jFTuwHsc2bS1yyq1R-4eS21hO9xpO9wO0E4D0suG6uMf9d91apLibJiDFlHq2Rz_kriJTeMSOfCi0Z9eoheHBqIxB7ZuK1T_3oBsxNChn1huIgfY_1QbtYTuhsig3rhDp9_C2nj6-Sg9Opx8egUPPANaDG0ofw2r9dVcv0HIVctNa2A_AFUQJb4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEB7aFNq8pG3apk4vFUKgsNpals_HsJtt0pZlIQmEvhhJlomT1Btib2Dz6zuSj6QXPcBPsjzWMaP5hEbfAGzlLDPx4WhIMlHUVzyiMkhcmsSuVoJHuVA22mIa7h35H4-D41upvrARFUqq7CG-seqLLG8ZBth7U35q4hZP9Ndh1OwX7sK9IGKeSV6wMzroF2HOPN4RhXvo4rtbc7-RYnyTqr73TT8Bzl_6JuuHJg_hS98DG35yNlzUcqiufyB3_K8uPoK1Fp2SnUadHsMdXa7Dg1GXFG4dtmcN1fVyQA5vbm5VA7JNZjck2MsncDm2oSEDcrAsEWNWBdYRZUZ2e3ZxMs9RRiGu5-cFOlBNvYFPM0OcRMZoFleWkbwiAh8ynV_pc2ITeJrPPqC5CBPDU2myX54UsjA5g57C0WT3cLRH2_wOVHA_rqnHcaVVmUKIykIRxsINpAiEF0vBgoz5uRsr3IAGWRJqRDksNPRq3BfS1SzWkeDPYKXEVj0HkgjJdBhJXyMElUomuVmbsJBLHkYqd-Adjmza2meV2qN3j6W2sB3utB1uB2inBelFQ_nxh_pvO1VJcTbMgYso9XyBf0ncxKZziRzYaHSol-jFoYFqzIGt20rVvzdgG7F06CeWo8gB9jfVRi2xuyE0qDf_odNv4P5sPEk_708_vYBVz2AXwx7KX8JKfbnQrxB51fK1tbFvpZkoOA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Design%2C+Synthesis%2C+and+Evaluation+of+Thiazolidine-2%2C4-dione+Derivatives+as+a+Novel+Class+of+Glutaminase+Inhibitors&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Yeh%2C+Teng-Kuang&rft.au=Kuo%2C+Ching-Chuan&rft.au=Lee%2C+Yue-Zhi&rft.au=Ke%2C+Yi-Yu&rft.date=2017-07-13&rft.eissn=1520-4804&rft.volume=60&rft.issue=13&rft.spage=5599&rft_id=info:doi/10.1021%2Facs.jmedchem.7b00282&rft_id=info%3Apmid%2F28609101&rft.externalDocID=28609101 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon |